Cargando…

A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38

The objective of this study was to develop a limited sampling model (LSM) to estimate the area under the curve (AUC) of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin (CPT‐11) and that of 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) as predictive pharmacokinetic variables for leukopenia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Yasutsuna, Mizuno, Shoichi, Fujii, Hirofumi, Ohtsu, Tomoko, Wakita, Hisashi, Igarashi, Tadahiko, Itoh, Kuniaki, Sekine, Ikuo, Miyata, Yoshinori, Saijo, Nagahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1995
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920588/ https://www.ncbi.nlm.nih.gov/pubmed/7737903 http://dx.doi.org/10.1111/j.1349-7006.1995.tb02996.x

Ejemplares similares

Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
por: Minami, Hironobu, et al.
Publicado: (2001)

Treatable Subsets in Cancer of Unknown Primary Origin
por: Sumi, Hajime, et al.
Publicado: (2001)

Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
por: van Ark-Otte, J., et al.
Publicado: (1998)

Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38
por: Sadzuka, Yasuyuki, et al.
Publicado: (1999)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging
por: Miya, Toshimichi, et al.
Publicado: (1992)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs
por: Ohtsu, Atsushi, et al.
Publicado: (1989)

Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations.
por: Itoh, K., et al.
Publicado: (1997)

Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11
por: Araki, Eiji, et al.
Publicado: (1993)

Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa Cells
por: Minagawa, Yukihisa, et al.
Publicado: (1994)

Progress in treatment of small-cell lung cancer: role of CPT-11
por: Saijo, N
Publicado: (2003)

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11
por: Ogasawara, Hayato, et al.
Publicado: (1995)

CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer
por: Yamamoto, Nobuyuki, et al.
Publicado: (1994)

Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells
por: TANAKA, TETSUJI, et al.
Publicado: (2012)

Investigation into the Efficacy of Val-SN-38, a Valine-Ester Prodrug of the Anti-Cancer Agent SN-38
por: Kwak, Eun-Young, et al.
Publicado: (2012)

The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP)
por: Ohmori, Tohru, et al.
Publicado: (1993)

Present Status and Problems on Molecular Targeted Therapy of Cancer
por: Saijo, Nagahiro
Publicado: (2012)

The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology
por: Saijo, Nagahiro
Publicado: (2013)

Highlights for ESMO 40: celebration review for lifetime achievement awards
por: Saijo, Nagahiro
Publicado: (2016)

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells
por: Yashiro, M, et al.
Publicado: (2011)

Synthesis, characterization, and evaluation of mPEG–SN38 and mPEG–PLA–SN38 micelles for cancer therapy
por: Xie, Jing, et al.
Publicado: (2016)

CPT and Superstring
por: Ellis, John R., et al.
Publicado: (1996)

LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN
por: Nakagawa, Kazuhiko, et al.
Publicado: (1988)

Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity
por: Shinkai, Tetsu, et al.
Publicado: (1989)

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level
por: Sano, Tetsuro, et al.
Publicado: (1988)

A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
por: Ando, M., et al.
Publicado: (1998)

CP, T and CPT at CPLEAR
por: Filipcic, Andrej, et al.
Publicado: (2001)

Tests of CPT with CPLEAR
por: Mikuz, M
Publicado: (2000)

Tests of CPT with CPLEAR
por: Adler, R, et al.
Publicado: (1996)

Test of CPT with antiprotons
por: Poth, Helmut
Publicado: (1978)

Cold antihydrogen and CPT
por: Gabrielse, G, et al.
Publicado: (2002)

Mechanism for CPT violation
por: Klinkhamer, F R
Publicado: (2001)

T and CPT in B-Factories
por: Bernabeu, J, et al.
Publicado: (2001)

Tests of CPT and CPT from neutral kaon semileptonic decays at the CPLEAR experiment
por: Go, Apollo Tao-ning
Publicado: (1995)

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
por: Sasaki, Yasutsuna, et al.
Publicado: (2014)

Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D)
por: Sasaki, Yasutsuna, et al.
Publicado: (1990)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_e9ipiq394brjhv65c5ruupgu3g